Phenytoin-associated movement disorder

Rissardo, Jamir Pitton; Caprara, Ana Letícia Fornari

doi:10.4103/tcmj.tcmj_74_22

Cited by 9 publications

(8 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Noteworthy, this presentation should have a differential diagnosis with Creutzfeldt-Jakob disease-like syndrome. A similar description was already reported with other drug-induced MCLs, such as phenytoin and lithium [80][81][82].…”

Section: Myoclonus (Mcl)-"ciproclonus"supporting

confidence: 79%

Fluoroquinolone-Associated Movement Disorder: A Literature Review

Rissardo

Caprara

2023

Medicines

View full text Add to dashboard Cite

Background: Fluoroquinolones (FQNs) are related to several central nervous system side effects. This review aims to evaluate the clinical-epidemiological profile, pathophysiological mechanisms, and management of FQNs-associated movement disorders (MDs). Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1988 and 2022. Results: A total of 45 reports containing 51 cases who developed MDs secondary to FQNs were reported. The MDs included 25 myoclonus, 13 dyskinesias, 7 dystonias, 2 cerebellar syndromes, 1 ataxia, 1 tic, and 2 undefined cases. The FQNs reported were ciprofloxacin, ofloxacin, gatifloxacin, moxifloxacin, levofloxacin, gemifloxacin, and pefloxacin. The mean and median age were 64.54 (SD: 15.45) and 67 years (range: 25–87 years). The predominant sex was male (54.16%). The mean and median time of MD onset were 6.02 (SD: 10.87) and 3 days (range: 1–68 days). The mean and median recovery time after MD treatment was 5.71 (SD: 9.01) and 3 days (range: 1–56 days). A complete recovery was achieved within one week of drug withdrawal in 80.95% of the patients. Overall, 95.83% of the individuals fully recovered after management. Conclusions: Future cases need to describe the long-term follow-up of the individuals. Additionally, FQN-induced myoclonus should include electrodiagnostic studies.

show abstract

Section: Myoclonus (Mcl)-"ciproclonus"supporting

confidence: 79%

Fluoroquinolone-Associated Movement Disorder: A Literature Review

Rissardo

Caprara

2023

Medicines

View full text Add to dashboard Cite

show abstract

“…Um dos sintomas clássicos da atrofia do cerebelo é a ataxia, descrita como uma das principais lesões irreversíveis que afetam a coordenação motora, sendo caracterizada pela realização de movimentos incertos, inseguros e descoordenados, imprecisão em alcançar uma posição da extremidade final e oscilações durante o curso do movimento, afetando diretamente a realização da marcha, (Ferner, 2022;Calsani, 2007;Rissardo & Caprara 2022). Com isto, o quadro motor do paciente se torna debilitado, pois a marcha é um fator essencial para a qualidade de vida dos indivíduos (Guirao-Bringas, & Díaz-Pérez, 2012).…”

Section: Resultsunclassified

Relato de caso: Atrofia cerebelar associada à intoxicação por Fenitoína em um munícipio da região amazônica

Araújo¹,

Simonetto²,

Souza³

et al. 2023

RSD

View full text Add to dashboard Cite

A ataxia cerebelar, é um dos sintomas clássicos da atrofia cerebelar, considerada também uma das principais lesões que afetam a coordenação motora, sendo de caráter irreversível interferindo na realização dos movimentos sendo estes incertos, inseguros, descoordenados e imprecisos, debilitando assim o quadro motor do paciente. Essa lesão cerebelar pode ser ocasionada a partir de doses elevadas associadas ao uso crônico da Fenitoína, um medicamento que pertence à classe das hidantoínas, um bloqueador dos canais de sódio, metabolizado pelo CYP2C9/10 hepático, é um dos antiepilépticos de primeira escolha para o tratamento/controle da epilepsia. Este relato destaca o caso de uma paciente que apresentou dificuldade na realização da marcha e consequentemente piora na coordenação motora, hiperplasia gengival e hirsutismo. Após investigação através de exames laboratorial e de imagem, foi confirmada a intoxicação por Fenitoína devido ao seu uso crônico e a atrofia do cerebelo desenvolvendo ataxia da marcha.

show abstract

“…Interestingly, the population affected by GBP-induced dystonia had a lower mean age when compared to the other GBP-induced movement disorders. It is worth mentioning that this is a common finding among drug-induced movement disorders [ 129 , 130 ]. Most individuals presented with segmental dystonia [ 95 ], but status dystonicus [ 19 ], generalized dystonia [ 96 ], and axial dystonia [ 98 ] were also observed.…”

Section: Discussionmentioning

confidence: 99%

Gabapentin-Associated Movement Disorders: A Literature Review

Rissardo,

Medeiros Araujo de Matos,

Fornari Caprara

2023

Medicines

View full text Add to dashboard Cite

Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized adverse drug reactions. They are commonly not discussed with patients, and their sudden occurrence can lead to misdiagnosis. This literature review aims to evaluate the clinical–epidemiological profile, pathological mechanisms, and management of GBP-associated MD. Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1990 and 2023. Results: A total of 99 reports of 204 individuals who developed a MD associated with GBP were identified. The MDs encountered were 135 myoclonus, 22 dyskinesias, 7 dystonia, 3 akathisia, 3 stutterings, 1 myokymia, and 1 parkinsonism. The mean and median ages were 54.54 (SD: 17.79) and 57 years (age range: 10–89), respectively. Subjects were predominantly male (53.57%). The mean and median doses of GBP when the MD occurred were 1324.66 (SD: 1117.66) and 1033 mg/daily (GBP dose range: 100–9600), respectively. The mean time from GBP-onset to GBP-associated MD was 4.58 weeks (SD: 8.08). The mean recovery time after MD treatment was 4.17 days (SD: 4.87). The MD management involved GBP discontinuation. A total of 82.5% of the individuals had a full recovery in the follow-up period. Conclusions: Myoclonus (GRADE A) and dyskinesia (GRADE C) were the most common movement disorders associated with GBP.

show abstract

Phenytoin-associated movement disorder

Cited by 9 publications

References 83 publications

Fluoroquinolone-Associated Movement Disorder: A Literature Review

Fluoroquinolone-Associated Movement Disorder: A Literature Review

Relato de caso: Atrofia cerebelar associada à intoxicação por Fenitoína em um munícipio da região amazônica

Gabapentin-Associated Movement Disorders: A Literature Review

Contact Info

Product

Resources

About